Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790
IRLAB announced today that a publication based on the clinical Phase Ib study with IRL790 in patients with Parkinson’s disease and dyskinesias has been published in the reputed scientific journal npj Parkinson’s Disease published by Nature.
IRL790 is one of IRLAB's leading drug candidates and is being developed for the treatment of dyskinesia and psychosis in Parkinson's disease. The clinical Phase Ib study shows that IRL790 is well tolerated and has a very good safety profile. Furthermore, the positive effect that dyskinesia decreased in the group treated with IRL790 was not shown in the placebo group. The drug candidate is now undergoing a clinical Phase IIa trial in a larger group of patients for further study of the effect observed in the Phase Ib study.
“Our study is now published in the journal npj Parkinson's Disease. This validates the research and is, of course, a major merit for IRLAB, our partners and the study's investigators," said Joakim Tedroff, Chief Medical Officer (CMO) at IRLAB.
npj Parkinson's Disease is an international journal, published by Nature, that highlights the most important scientific advances in Parkinson’s disease research.
The publication: Svenningsson, P. et al. Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial. npj Parkinson’s Disease. DOI number 10.1038/s41531-018-0071-3.
Link to npj Parkinson’s Diesease: www.nature.com/npjparkd/